Core Viewpoint - Novo Nordisk has received FDA approval for the first oral weight loss drug, a GLP-1 pill specifically for obesity, set to launch in early 2026 [1][2]. Group 1: Product Details - The new oral drug is priced at approximately $150 per month before insurance, which is significantly lower than existing injection options [2]. - This oral medication represents a major advancement in obesity treatment, providing patients with an alternative to injections [2]. Group 2: Market Impact - The CEO of Novo Nordisk, Mike Dutar, indicated that the approval will significantly expand the market for obesity treatments, as many individuals are hesitant to use injections due to fear of needles or societal stigma [3]. - The introduction of a pill option is expected to attract a broader patient base who may have previously avoided treatment due to the injection format [3].